● Recruiting

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

Condition: Multiple Sclerosis · Sponsor: Novartis Pharmaceuticals

PhasePhase 4

Planned participants30

Who can joinAll sexes, 20 Years to 100 Years

Healthy volunteersNo

About this study

The purpose of the study is to describe the safety profile of fingolimod in the Taiwanese multiple sclerosis population. This study aims to collect the safety data in patients newly initiated on fingolimod for one year.

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com

Novartis Pharmaceuticals

Always discuss trial participation with your own doctor first.

Locations (6)

Novartis Investigative Site	Kaohsiung City, Taiwan	Recruiting
Novartis Investigative Site	Taichung, Taiwan	Recruiting
Novartis Investigative Site	Tainan, Taiwan	Withdrawn
Novartis Investigative Site	Taipei, Taiwan	Recruiting
Novartis Investigative Site	Taipei, Taiwan	Withdrawn
Novartis Investigative Site	Taoyuan, Taiwan	Withdrawn

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04480853